Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
HTRF (BCL2L1)
Assay data:1 Tested
SummaryRelated BioAssays by Target
Inhibition of N-terminal GST-tagged Bcl-xL (1 to 209 residues) expressed in Escherichia coli /human Bak measured for 60 mins by by TR-FRET based LanthaScreen Eu-Kinase binding assay
SummaryPubMed CitationRelated BioAssays by Target
Displacement of fluorescein tagged BID BH3 peptide from GST-tagged recombinant Bcl-xl (unknown origin) by fluorescence polarization-based competitive binding assay
Assay data:1 Active, 1 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Inhibition of Bcl-xl (unknown origin)
Assay data:2 Active, 2 Activity ≤ 1 µM, 2 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Binding affinity to Bcl-xL (unknown origin) assessed as inhibition constant by TR-FRET assay
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
Binding affinity to His-tagged Bcl-xL (unknown origin) assessed as inhibition constant by competitive fluorescence polarization assay
Assay data:1 Activity ≤ 1 nM, 1 Activity ≤ 1 µM, 1 Tested
SummaryCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Binding affinity to Bcl-xL (unknown origin) assessed as inhibition constant by competitive fluorescence polarization assay
Binding affinity to Bcl-xL (unknown origin) assessed as inhibition constant
Inhibition of BH3 peptide binding to Bcl-xL (unknown origin)
Binding affinity to recombinant His-tagged human Bcl-xL expressed in Escherichia coli assessed as inhibition constant by SPR analysis
Assay data:2 Active, 1 Activity ≤ 1 nM, 2 Activity ≤ 1 µM, 2 Tested
Binding affinity to BCL-xL (unknown origin) assessed as inhibition constant
Assay data:6 Active, 13 Tested
Fluorescence Polarization Competition Assay from US Patent US11760752: "Carboxylic acid, acyl sulfonamide and acyl sulfamide-derivatized bicyclic aza-heteroaromatics as selective Mcl-1 inhibitors and as dual Mcl-1/Bcl-2 inhibitors"
Assay data:40 Active, 34 Activity ≤ 1 µM, 44 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
Bcl-2 and Bcl-xL Inhibition Assay from US Patent US11718613: "N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors"
Assay data:19 Active, 1 Activity ≤ 1 nM, 19 Activity ≤ 1 µM, 19 Tested
Biological Activity Assay from US Patent US11718611: "Benzenesulfonylbenazamide compound for inhibiting BCL-2 protein and composition and use thereof"
Assay data:1 Active, 1 Activity ≤ 1 nM, 1 Activity ≤ 1 µM, 1 Tested
BCL-XL TR-FRET Assay from US Patent US11697650: "Compounds having tetrahydroindolizine-1-carboxamide as BCL-2 inhibitors"
Assay data:21 Active, 36 Tested
SummaryCompounds, ActiveRelated BioAssays by DepositorRelated BioAssays by Target
Bcl-2 Protein Family Binding Assay from US Patent US11590126: "Benzamide compounds"
Assay data:28 Active, 28 Activity ≤ 1 µM, 28 Tested
PROTAC activity at CRBN/BCL-XL in human MOLT-4 cells assessed as induction of BCL-XL degradation incubated for 16 hrs by Western blot analysis
Selectivity interaction (TR-FRET assay) EUB0000746a BCL2L1
Selectivity interaction (TR-FRET assay) EUB0000263b BCL2L1
Affinity Biochemical interaction (TR-FRET assay) EUB0000262b BCL2L1
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on